Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition.
CSCs
EMT
HCC
SLAMF3
sorafenib resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Feb 2022
12 Feb 2022
Historique:
received:
14
01
2022
revised:
07
02
2022
accepted:
08
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Acquired resistance to sorafenib in hepatocellular carcinoma (HCC) patients results in poor prognosis. Epithelial-to-mesenchymal transition (EMT) is the major mechanism implicated in the resistance to sorafenib. We have reported the tumor suppressor role of SLAMF3 (signaling lymphocytic activation molecules family 3) in HCC progression and highlighted its implication in controlling the MRP-1 transporter activity. These data suggest the implication of SLAMF3 in sorafenib resistance mechanisms. We evaluated the resistance to sorafenib in Huh-7 cells treated with progressive doses (Res cells). We investigated the link between acquired resistance to sorafenib and SLAMF3 expression by flow cytometry and Western blot methods. Furthermore, we analyzed the EMT and the stem cell potential of cells resistant to sorafenib. Sorafenib resistance was confirmed in Res cells by analyzing the cell viability in the presence of sorafenib. The mesenchymal transition, in Res cells, was confirmed by high migratory index and the expression of EMT antigens. Interestingly, we found that loss of SLAMF3 expression corresponded to sorafenib-resistant phenotypes. The overexpression of SLAMF3 reversed EMT, decreased metastatic potential and inhibited mTOR/ERK1/2 in Res cells. We propose that rescuing SLAMF3 expression in resistant cells could represent a potential therapeutic strategy to enhance sorafenib efficacy in HCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Acquired resistance to sorafenib in hepatocellular carcinoma (HCC) patients results in poor prognosis. Epithelial-to-mesenchymal transition (EMT) is the major mechanism implicated in the resistance to sorafenib. We have reported the tumor suppressor role of SLAMF3 (signaling lymphocytic activation molecules family 3) in HCC progression and highlighted its implication in controlling the MRP-1 transporter activity. These data suggest the implication of SLAMF3 in sorafenib resistance mechanisms.
METHODS
METHODS
We evaluated the resistance to sorafenib in Huh-7 cells treated with progressive doses (Res cells). We investigated the link between acquired resistance to sorafenib and SLAMF3 expression by flow cytometry and Western blot methods. Furthermore, we analyzed the EMT and the stem cell potential of cells resistant to sorafenib.
RESULTS
RESULTS
Sorafenib resistance was confirmed in Res cells by analyzing the cell viability in the presence of sorafenib. The mesenchymal transition, in Res cells, was confirmed by high migratory index and the expression of EMT antigens. Interestingly, we found that loss of SLAMF3 expression corresponded to sorafenib-resistant phenotypes. The overexpression of SLAMF3 reversed EMT, decreased metastatic potential and inhibited mTOR/ERK1/2 in Res cells.
CONCLUSIONS
CONCLUSIONS
We propose that rescuing SLAMF3 expression in resistant cells could represent a potential therapeutic strategy to enhance sorafenib efficacy in HCC patients.
Identifiants
pubmed: 35205659
pii: cancers14040910
doi: 10.3390/cancers14040910
pmc: PMC8869973
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Pharmacol Exp Ther. 2011 Apr;337(1):155-61
pubmed: 21205925
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancer Sci. 2005 Jul;96(7):379-86
pubmed: 16053508
Biomed Res Int. 2014;2014:460654
pubmed: 25126561
World J Hepatol. 2010 Mar 27;2(3):114-26
pubmed: 21160982
J Hematol Oncol. 2019 Apr 11;12(1):37
pubmed: 30971294
Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1269-77
pubmed: 18808443
Mol Oncol. 2019 May;13(5):1311-1331
pubmed: 30959553
Curr Opin Cell Biol. 2018 Dec;55:30-35
pubmed: 30006053
J Tissue Eng Regen Med. 2020 Feb;14(2):257-271
pubmed: 31713308
Oncotarget. 2016 Mar 1;7(9):9832-43
pubmed: 26799423
Oncol Lett. 2018 Jun;15(6):9377-9384
pubmed: 29928334
PLoS One. 2017 Sep 21;12(9):e0185088
pubmed: 28934275
Oncotarget. 2016 May 31;7(22):32493-503
pubmed: 27081035
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
PLoS One. 2013 Dec 20;8(12):e82918
pubmed: 24376606
Cancers (Basel). 2017 Sep 20;9(9):
pubmed: 28930164
Cancer Lett. 2017 Jul 10;398:12-21
pubmed: 28377178
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Clin Invest. 2010 Apr;120(4):1031-4
pubmed: 20335655
World J Gastroenterol. 2017 Oct 7;23(37):6750-6776
pubmed: 29085221
PLoS One. 2013 Nov 11;8(11):e78675
pubmed: 24244338
Oncotarget. 2016 Feb 9;7(6):7207-15
pubmed: 26769852
Br J Cancer. 2012 Jun 5;106(12):1997-2003
pubmed: 22596232
Oncogene. 2005 Dec 15;24(56):8277-90
pubmed: 16116478
Hepatology. 2015 Aug;62(2):534-45
pubmed: 25902734
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Sci Rep. 2016 Mar 11;6:22976
pubmed: 26964667
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):564-570
pubmed: 29054475
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
BMC Med. 2009 Aug 24;7:41
pubmed: 19698189
Int J Cancer. 2015 Feb 15;136(4):E161-72
pubmed: 25053293